Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

The Latest From Jayson MacLean

Haivision Systems is a Buy, says Paradigm

Analysts xpof

Xponential Fitness is a Buy, says Roth

Analysts Pharma and Biotech fusn

Fusion Pharmaceuticals has tons of upside, says Raymond James

Analysts Pharma and Biotech arch

Arch Biopartners is a pass, says Raymond James

AI Analysts aif cts cvo dcbo dtol kxs mvp otex prl quis sbio well wish

13 AI stocks for your portfolio

Analysts Pharma and Biotech eprx

Eupraxia Pharmaceuticals is a Strong Buy, says Raymond James

Analysts Marketing wish

Wishpond Technologies wins Buy recommendation from Haywood

Analysts Pharma and Biotech mset

Mindset Pharma has tons of upside, says Echelon

Cannabis ter

CNSX:TER is still a Buy, Beacon says

American Tech Analysts META

Still more upside to Meta Platforms, says Roth

Analysts Pharma and Biotech fusn

Fusion Pharmaceuticals is a triple, says Raymond James

Analysts Pharma and Biotech mdp

Medexus Pharmaceuticals has an Outperform rating with Raymond James

Analysts Health well

WELL Health is still a Buy, says Haywood

Analysts Cannabis ter

CNSX:TER keeps “Buy” rating with Clarus

Analysts Software note

FiscalNote stock is a Buy, says Roth Capital

Analysts Pharma and Biotech mnmd

Mind Medicine has a huge upside, says Roth

Analysts Software kxs

Kinaxis is a Buy, says ATB Capital

Analysts Life Sciences sva

Sernova stock is a four-bagger from here, says Research Capital

Analysts de

Decisive Dividend is a Buy, says Beacon

Analysts Cleantech plug

Plug Power is a Buy from here, says Roth

Analysts Cleantech bldp

Ballard Power is still a pass, says Roth

Analysts aep

Atlas Engineered Products keeps Buy rating with Beacon

Analysts quis

Quisitive Technology Solutions is a Buy, says Eight Capital

Analysts Cannabis hiti

High Tide is a Buy, says Beacon Securities

Analysts Pharma and Biotech sva

Sernova is significantly undervalued, says Echelon

Analysts Cannabis acb

Take a pass on ACB stock (TSX:ACB), says Roth

Analysts Pharma and Biotech vph

Valeo Pharma has a 178 per cent upside, says Echelon

Analysts Resource Tech neo

Is Neo Performance Materials stock a buy (June, 2023)?

Analysts Pharma and Biotech vph

Beat the market with Valeo Pharma stock, says Research Capital

Analysts Cleantech Resource Tech maxn

Maxeon Solar has a 40 per cent upside, says Roth

Get Stock Picks from the Pros. In your Inbox.